HPK1
Hematopoietic progenitor kinase 1 (HPK1), a negative regulator of the T-cell receptor signaling pathway. Inhibiting HPK1 can enhance antitumor immune responses, making it a prominent drug target in immuno-oncology. Compounds targeting HPK1 are evaluated at the cellular level using metrics such as cellular IC50 to assess potency.
Timeline (last 90 days)
In a prospective HPK1 study, DrugHarness achieved more favorable median docking scores than Biomni among system-specific candidate molecules.
A synthetic compound designed by DrugHarness achieved a cellular IC50 of 14.19 nM, a 2.64-fold potency improvement over the best input reference molecule, with activity comparable to selected compounds designed by two senior medicinal chemists.
HPK1 (hematopoietic progenitor kinase 1) is a negative regulator of the T-cell receptor signaling pathway, and inhibiting HPK1 can enhance anti-tumor immune responses, making it a hot target in immuno-oncology.
All Facts (3)
In a prospective HPK1 study, DrugHarness achieved more favorable median docking scores than Biomni among system-specific candidate molecules.
50%UnverifiedA synthetic compound designed by DrugHarness achieved a cellular IC50 of 14.19 nM, a 2.64-fold potency improvement over the best input reference molecule, with activity comparable to selected compounds designed by two senior medicinal chemists.
50%UnverifiedHPK1 (hematopoietic progenitor kinase 1) is a negative regulator of the T-cell receptor signaling pathway, and inhibiting HPK1 can enhance anti-tumor immune responses, making it a hot target in immuno-oncology.
50%